When does DBV.PA stock report earnings and why does it matter?

DBV.PA stock reports earnings on 23 Mar 2026 and investors will use the release to check cash runway, BLA timelines for VIASKIN Peanut, and guidance that can change near-term valuation.

What is Meyka AI’s view and grade for DBV.PA stock?

Meyka AI rates DBV.PA **67.23/100**, Grade **B** (HOLD). The grade combines sector comparison, financial growth, key metrics, and analyst signals; it is informational, not a recommendation.

What price targets and forecast exist for DBV.PA stock?

Meyka AI's forecast model projects **€4.16** in 12 months (implied **+20.66%**) and a near-term quarterly level of **€4.91**. These are model projections and not guarantees.

What are the main risks investors should watch for DBV.PA stock?

Key risks for DBV.PA stock include regulatory delays on BLAs, less favorable label or pricing, higher-than-expected commercial costs, and cash burn that could force dilution or slower launches.

EU Stocks

BLA timeline: DBV.PA DBV Technologies Euronext pre-market 18 Mar 2026: earnings

ByHuzaifa Zahoor March 18, 2026March 18, 2026

DBV.PA stock opens pre-market under close scrutiny as DBV Technologies advances two Biologics License Application (BLA) filings for VIASKIN Peanut and prepares an earnings update on 23 Mar 2026. Investors will watch regulatory timing, cash runway and commercial readiness from France-listed DBV Technologies on Euronext. At €3.45 with daily range €3.42–€3.54 and volume 487881.00, the company’s clinical results and launch commentary are the main drivers before the report.